In the current study, the induction of persistent tumor immunity by pIL-12 GET combined with anti-PD1 in tumor-bearing mice was supported by (a) successful resistance to tumor cells rechallenge, (b) improved levels of antigen-specific cytotoxic T lymphocytes responses in vitro, (c) elevation in the total numbers of CD4 and CD8 T cell populations in the tumor milieu, (d) raised number of activated/memory CD8+ T cell subpopulations in the spleens of treated mice. The gene discussed is CD4; the disease is neoplasm.